![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Lead Product(s): Glycine,Calcium
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nozohaem
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: $48.6 million Upfront Cash: $48.6 million
Deal Type: Acquisition September 05, 2023